Skip to content
Our 2022 Year in Review is now live.
  • Insights

      Weekly Bulletin

      Your weekly recap of news and analysis from the psychedelic sector.

      Read the Latest

      Research Review

      A monthly review of the most important psychedelics research.

      Review Archive

      News & Interviews

      The latest news from across the psychedelics space.

      Explore Now
  • Data

      Psychedelics Patent Trackers

      We track the latest patents and filings related to psilocybin, MDMA and DMT.

      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents
      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents

      Psychedelic Legalization & Decriminalization Tracker

      Mapping psychedelic drug policy reform across the United States

      Explore the Tracker
      New: Oregon Local Jurisdiction Tracker

      Psychedelics Drug Development Tracker

      From drug discovery to regulatory approval, we map drug development in psychedelics.

      Explore the Tracker
  • Companies

      Stocks & Companies Directory

      A directory of all the major psychedelics stocks, companies and ETFs.

      Access Directory

      Sector Landscape Map

      Explore the Psychedelic Sector Landscape visually using our new tool.

      Explore Now

      Stock Watchlist

      A one-stop overview of psychedelics stocks financial performance.

      Explore Now
  • Psychedelic Careers
  • Contact
Search
Close
Read more about the article MagicMed to Be Acquired by Nasdaq-Listed Company

MagicMed to Be Acquired by Nasdaq-Listed Company

  • Post published:May 24, 2021
  • Post category:Analysis/News
Read more about the article MindMed Becomes Second Psychedelic Drug Development Company to List on the Nasdaq

MindMed Becomes Second Psychedelic Drug Development Company to List on the Nasdaq

  • Post published:April 27, 2021
  • Post category:News
Read more about the article Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

  • Post published:March 2, 2021
  • Post category:Analysis/News
Read more about the article UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

  • Post published:January 27, 2021
  • Post category:Analysis/News
Read more about the article North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF?

North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF?

  • Post published:January 21, 2021
  • Post category:Analysis/News
Read more about the article First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK)

First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK)

  • Post published:December 28, 2020
  • Post category:Analysis/News
Read more about the article Beckley Psytech Raises £14m ($18.6m) to Advance Development of 5-MeO-DMT for Neuropsychiatric Diseases

Beckley Psytech Raises £14m ($18.6m) to Advance Development of 5-MeO-DMT for Neuropsychiatric Diseases

  • Post published:December 19, 2020
  • Post category:News
Read more about the article Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment

Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment

  • Post published:December 12, 2020
  • Post category:Analysis/News
Read more about the article UK Regulators Approve World’s First DMT for Depression Clinical Trial

UK Regulators Approve World’s First DMT for Depression Clinical Trial

  • Post published:December 10, 2020
  • Post category:News
Read more about the article Research Suggests Past Antidepressant Usage Reduces Efficacy of MDMA-Assisted Psychotherapy for PTSD

Research Suggests Past Antidepressant Usage Reduces Efficacy of MDMA-Assisted Psychotherapy for PTSD

  • Post published:November 23, 2020
  • Post category:News

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Psychedelic Stocks and Companies
  • News & Interviews
  • Psychedelic Sector Jobs
  • Data Bank

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

  • Psychedelic Alpha © 2022, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.